Haemodynamics alone do not fully explain symptoms and prognosis in clinically severe aortic stenosis (AS). Myocardial disease, specifically diffuse myocardial fibrosis (DMF), may contribute. We used equilibrium contrast cardiovascular magnetic resonance (EQ-CMR) and sought to non-invasively measure DMF in severe AS and determine its clinical significance before and after valve replacement.
Introduction
Aortic stenosis (AS) is the most common valve lesion requiring surgery in the Western World 1 with 3% of over 75-year olds affected by severe AS. 2 The symptoms of AS (breathlessness and exercise limitation) are highly variable and are not fully explained by any single parameter or multivariable model. 3, 4 Biopsy data demonstrate that left ventricular (LV) hypertrophy in AS is associated with increased DMF 5 and this is correlated with cardiomyocyte degeneration resulting in diastolic dysfunction and eventually heart failure. 6 Cardiovascular magnetic resonance (CMR) is the gold standard method of assessing focal fibrosis using late gadolinium enhancement (LGE) and this has also been shown to be important in AS, correlating with New York Heart Association (NYHA) status and markers of systolic function. 7 However, the
LGE technique misses diffuse fibrosis, which requires invasive endomyocardial biopsy for its quantification. We have developed a non-invasive technique to measure diffuse fibrosis-equilibrium contrast CMR (EQ-CMR) which has been validated against histology in patients with severe AS. 8 Using EQ-CMR, the volume of distribution of contrast in the myocardium (Vd (m) ) can be derived and this correlates strongly with the percentage of diffuse fibrosis. We hypothesized that (i) diffuse fibrosis would be elevated in disease vs. normal hearts and (ii) diffuse fibrosis would be associated with baseline symptoms and symptomatic response to aortic valve replacement (AVR) in patients with AS.
Methods
All research was carried out at University College London Hospital NHS Trust, London between October 2008 and January 2011. An ethics committee of the UK National Research Ethics Service approved the study. Analyses were performed blinded. All patients gave informed consent to take part in the study.
Patient population
Sixty-six consecutive patients with severe AS accepted for surgical AVR were prospectively enrolled (18 of these patients were also studied in a technical validation study). 8 Exclusion criteria included contraindication to CMR (pacemakers) or gadolinium (glomerular filtration rate ,30 mL/min/m 2 ); or uncontrolled arrhythmia. The primary surgical indication was severe AS but 18 patients had additional coronary artery bypass grafting and 7 had more than mild aortic regurgitation. Thirty controls (defined by a healthy heart questionnaire, normal electrocardiogram, and normal blood pressure) underwent EQ-CMR. Patients underwent baseline and 6-month post-operative assessment with the history (to include NYHA, Canadian Cardiovascular Society angina score, and past medical history), echocardiography, blood tests [brain natriuretic peptide (BNP), full blood count for the haematocrit], 6 min walk test (6MWT), and CMR (including repeat EQ-CMR).
Investigations
The 6MWT was performed using standard methods. 9 Sixteen patients did not perform the walk test (3 refused, 2 were unable to follow instructions appropriately, and 11 due to either co-morbidity (prior stroke, balance/musculoskeletal) or rescheduled operation slot]. Conventional two-dimensional echocardiography was performed. 10 Diastolic function was graded according to the mitral inflow pattern (I, II, III, IV), pulmonary vein flow, and tissue Doppler indices at the mitral annulus taking into account calcification extending from the aortic valve. 11 Some echocardiograms (n ¼ 4) were performed in the referring hospital and the images could not be obtained for core lab review. Standard CMR examination 12 was performed in all patients on a 1.5T scanner (Avanto, Siemens, Erlangen, Germany). For LGE imaging, 0.1 mmol/kg, Dotarem (Guerbet, SA) was administrated intravenously and standard breath-hold, inversion recovery imaging performed with phase swaps when appropriate. 10 -12 EQ-CMR was performed as previously described. 8 In brief, this involves three steps: (i) a primed contrast (Dotarem) infusion to induce contrast equilibrium [bolus 0.1 mmol/kg followed 15 min later by a continuous infusion of (0.0011 mmol/kg/min) over 30 -60 min-max dose ,0.2 mmol/kg]; (ii) CMR to measure signal (T1) pre-and postequilibrium; and (iii) measurement of the blood contrast volume of distribution (equal to 1 minus haematocrit).
Image analysis
Myocardial volumes and mass analyses were carried out using standard techniques. 12 Impaired LV function was defined as an ejection fraction ,60%.
LGE quantification was performed using the full width at half maximum technique to determine LGE mass (g) and LGE % per patient 13, 14 and expressed continuously and as binary variables (present/absent). Vd (m) was calculated as previously described (from a region of interest drawn in the basal septum) and converted to percentage of diffuse myocardial fibrosis (DMF%) using the correlation line fit of Vd (m) against collagen volume fraction from a subset of 18 patients (who were no different in terms of age, sex, diabetes, hypertension, and concomitant coronary artery bypass ratios to the entire population studied here) who underwent intraoperative biopsy. 8 DMF was expressed continuously and in tertiles (low, mid, and high). Although myocardium has a density of 1.05 g/mL, the relative densities of its components (fibrosis and cell volume) are not known, so we expressed these in millilitres rather than milligrams. Fibrosis volume (mL) was calculated as DMF% * LV mass/1.05 and cell volume (mL) as 100% minus DMF% * LV mass/1.05.
Data analysis and statistics
Data are expressed as mean + standard deviation or median and interquartile range (for normal and non-normally distributed data, respectively). In a random selection of 20 patients, image analysis (ROI drawing, T1 calculation, and Vd (m) calculation) was performed twice by the primary observer (author ASF, blinded to the first analysis and temporally separated by a minimum of 6 months) and once by a second observer (DMS) with the reproducibility analysis (intra-and interobserver) performed by intra-class correlation coefficient 15 (ICC). Bland -Altman 16 testing was performed in order to assess for systematic offset and the relation of observed differences to fibrosis extent. Group mean comparisons were performed using Student's t-test (two groups) or analysis of variance (ANOVA) with post hoc Bonferroni correction (more than two groups). Univariate association of normally distributed data were tested with Pearson's test. Univariate associations between continuous outcomes and ordered variables were measured using Spearman's rho correlation coefficient. Since BNP was not normally distributed, a natural log transformation was performed and this was used in the analysis. Multivariable analyses of associations were performed using linear regression with variable selection in a single step. The variables entered in the models are those listed in Tables 3 and 4 . A P-value of ,0.05 was considered significant. SPSS 17 version 17 was used for statistical analyses.
Role of the funding source
The funding source (British Heart Foundation) peer reviewed the original grant application but had no role in study design, collection, analysis, interpretation, writing, or decisions with regard to publication.
Results
Baseline characteristics are listed in Table 1 . There was no significant difference between the age, gender ratio, or body mass index between normals and patients. Sixty-six patients underwent EQ-CMR at baseline. Three of these were excluded (two had unexpected fast uncontrolled atrial fibrillation and one unable to breath-hold). Forty-four patients underwent EQ-CMR at the followup, two of which were excluded from the analysis (due to new valve disease-severe mitral regurgitation and severe aortic regurgitation sufficient to require repeat surgery). Patients did not undergo EQ-CMR follow-up for the following reasons: 5 patients had died, 12 patients had received non-MRI compatible permanent pacemakers, 2 patients declined repeat investigation, and 2 patients did not undergo AVR due to a porcelain aorta at surgery. This left 63 and 42 patients in baseline and follow-up analyses.
Reproducibility
Analysis was reproducible (inter-and intraobserver, 
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Baseline data DMF% was elevated compared with normal controls (18.1 + 8.1 vs. 13.4 + 6.5%, P ¼ 0.007), but with considerable overlap (Figure 1 ). Mean DMF% was not different in the presence of ischaemic heart disease, hypertension, diabetes, or more than mild aortic regurgitation. Twenty-eight patients had LGE (6 had infarct pattern, the remainder were either RV insertion point or atypical, intermediate signal intensity; mean LGE% ¼ 7.1 in those where LGE was observed). There was no correlation between age and DMF%. In AS, DMF% correlated with the aortic valve area (inversely, r 2 ¼ 0.17, P ¼ 0.001) but not with the mean and peak aortic velocities. DMF% did not correlate with overall ejection fraction, but there was an association when LV impairment was present (n ¼ 11, Figure 2 ). Factors associated with baseline 6MWT were DMF% and BNP (univariate inverse correlations, r 2 ¼ 0.22, P ¼ 0.001 and r 2 ¼ 0.14, P ¼ 0.05, respectively, Figure 2 and Table 3 ). On multivariable analysis (including eight classically associated variables, 9 see Table 3 for those included in the analysis), only DMF% and BNP were associated. The most significant association was with DMF% (P ¼ 0.003 vs. P ¼ 0.02, respectively).
Post-operative data
Mean time at follow-up was 194 + 24 days. Patients improved significantly following AVR (LV end-diastolic volume, stroke volume, mass, left atrial area, 6MWT, and BNP, Figure 3 ). On univariate analysis, only DMF% and preop 6MWT correlated with the change in 6MWT (r 2 ¼ 0.18, P ¼ 0.007, and r 2 ¼ 0.24, P , 0.001, Table 4 ). On multivariable analysis, of the nine variables assessed as potential predictors of 6MWT improvement, only preoperative 6MWT correlated with the change in 6MWT (P ¼ 0.024). Of the five deaths over 6-month follow-up, four were in the highest DMF tertile group. LV hypertrophy regressed after AVR (205 + 54 to 178 + 51 g, P , 0.001). DMF% did not change (18 + 8 to 19+ 7%, P ¼ 0.47) nor did fibrosis volume (36 + 21 to 33 + 18 mL, P ¼ 0.54). The total cell volume fell (157 + 42 to 137 + 38 mL, P , 0.001, Figure 4) showing that LVH regression at 6 months was cellular rather than fibrosis resolution.
Discussion
DMF extent varies widely in patients from entirely normal in many, to more than one-third of the volume of the heart in others. It is relatively independent of other factors known to be important in AS but was the strongest determinant of functional status at baseline in this study. Of the five deaths, four occurred in the patients in the highest tertile of fibrosis. Diffuse fibrosis was not reversible 6 months after AVR; the LV hypertrophy regression observed was demonstrated as cellular regression-a result that corroborates animal data 18 and previous biopsy data from 20 years ago. 19, 20 Overall, the association between diffuse fibrosis, BNP, and symptoms in AS supports a role for myocardial disease in severe AS. From a methodological perspective, the EQ-CMR technique is shown here to be promising. It is the first robust, histologically Data points in 2% bins, P-value from unpaired Student's t-test, solid line indicates mean for the group. DMF% is significantly lower in normals (n ¼ 30) than in patients with AS but with a large overlap (n ¼ 63, P ¼ 0.007, error bars represent 95% confidence intervals).
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validated non-invasive diffuse fibrosis quantification technique. The considerable overlap between patients and normals in this study may limit the clinical utility of the method in AS.
Exercise impairment in AS
AS raises the LV pressure with initial compensatory LV hypertrophy which later becomes maladaptive 6 leading to reduced coronary flow reserve, impaired diastolic and then systolic function through a variety of mechanisms, including ischaemia, altered calcium handling, apoptosis, neurohumoural activation, and focal and DMF. 5 -8 Animal study demonstrates up-regulation of profibrotic genes in models of LV hypertrophy which completely normalize with after-load reduction and LV hypertrophy regression. 18 Biopsy data have demonstrated that increased diffuse fibrosis is associated with these profibrotic genes along with diastolic dysfunction. 5 These key final common pathway processes have been occult clinically but are now within reach of non-invasive assessment. An interesting finding in this study is the fate of patients with most fibrosis: they are more symptomatic at baseline, improve the most post-operatively and yet carry a trend towards increased mortality. To unravel this, further studies will be required to track diffuse fibrosis earlier in the disease and in a larger cohort to understand how to use it as a treatment guide or prognostic marker. DMF did not improve at 6 months, although cellular regression occurred. Biopsy studies suggest that diffuse fibrosis regression may still occur over a longer time frame. 19 
Limitations
This was a preliminary study and as such was relatively small resulting in some known but weak predictors of functional recovery after AVR (e.g. EF%) failing to do so. We did not measure any parameter of systolic performance corrected for afterload. The EQ-CMR technique as implemented here requires 10 min extra scanning time and up to 1 h extra in the CMR department. The method we employed enables imaging of a single slice of the heart. New single breath-hold T1 mapping sequences are faster (potentially facilitating whole heart diffuse fibrosis quantification), 21 and a short infusion-or even no infusion may be possible. 22 This study necessarily excluded patients with pacemakers and was potentially arrhythmia sensitive. Biopsies were only done intra-operatively and not at follow-up-it is possible that after-load reduction alters histology to mimic cellular regression, although this is unlikely given the results reproduce a known previous finding. 23 The follow-up was at 6 months and so conclusions about the long-term permanence of diffuse fibrosis cannot be drawn. Patients received a mix of mechanical and tissue valves, some had coronary disease including evidence of hyperenhancement on LGE imaging and some had aortic regurgitation reducing the power of the study for pathophysiological insights (but increasing real-world relevance). Finally, on the basis of the results here, it is difficult to predict the clinical role of DMF% measurement, but it would seem that further work is justified. In particular, we have only studied severe AS awaiting AVR: study of AS earlier in the disease process is needed.
Conclusion
DMF as measured by EQ-CMR is important in AS. These data support the concept that myocardial disease is an important component of the clinical phenotype in AS.
Supplementary data
Supplementary data are available at European Heart JournalCardiovascular Imaging online. 
